A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies
Trial details
- Registry ID
- NCT05301517
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Recombinant human erythropoietin-α [rHuEPO-α]
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid MalignanciesNCT05301517 | Kyntra Bio | Phase 3 | Completed | 2023-04-03Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |